<p>, /PRNewswire/ -- Insight Lifetech，启明创投的投资组合公司，作为中国领先的创新医疗器械制造商，于 2026 年 2 月 5 日北京时间成功在上海证券交易所科创板上市。Insight Lifetech (688712.SH) 以每股 17.52 元人民币的价格发行股票，开盘价为每股 50.31 元人民币，市值为 209.8 亿元人民币。</p>
<p>启明创投在 2020 年主导了 Insight Lifetech 的 C 轮融资，并在 D 轮继续支持公司的发展。在公司上市前，启明创投持有 Insight Lifetech 超过 6% 的股份，是其主要机构投资者之一。</p>
<p>Insight Lifetech 成立于 2015 年，致力于开发具有潜力改变心血管疾病精准诊断和治疗的创新解决方案。该公司是中国唯一一家在精准血管生理学和成像领域拥有产品组合的国内医疗器械公司，包括中国首个也是唯一一个获得 NMPA 批准的分数流量储备（FFR）系统，以及进入临床试验并完成患者招募的首个国内血管内超声（IVUS）系统。</p>
<p>自成立以来，Insight Lifetech 根据心血管疾病诊断的临床需求和前沿技术的发展，持续投资于冠状动脉疾病、外周血管疾病和房颤等领域。现在已将 11 款产品推向市场，并在多种类别中开发更多产品，包括 IVUS 系统、FFR 系统、血管通路产品和电生理解决方案等。</p>
<p>公司的核心产品 IVUS 系统是中国首个自主研发的 60MHz 高清高速 IVUS 产品，也是首个获得 CE MDR 批准的中国制造产品。该产品在上市后迅速获得了中国市场的最大份额，减少了国家对进口产品的依赖。公司的另一核心产品 FFR 系统是中国首个获得批准的国产 FFR 产品，也是首个获得海外（由 CE MDR）批准的中国制造产品。这两款产品预计将有助于提升精准导向经皮冠状动脉介入（PCI）手术的临床实践。</p>
<p>Insight Lifetech 的创始人、董事长兼首席执行官宋亮表示：&#34;自成立以来，Insight Lifetech 始终坚持 ‘通过创新和质量改变医疗保健’ 的使命，致力于创新智能化精准心血管介入。凭借坚定的热情和不懈的努力，我们填补了中国医疗器械行业的一个关键空白——这是一个技术壁垒最高、产业链最长的领域：高性能精准心血管介入设备。</p>
<p>展望未来，我们将继续保持在精准心血管介入创新的前沿，保持临床聚焦，追求无可妥协的质量，向世界展示中国创新的强大力量。&#34;</p>
<p>&#34;Insight Lifetech 深切致力于将临床洞察和技术能力转化为心血管介入领域的创新和差异化疗法，造福全球患者和医生。这个专注的团队让我们相信它能够在创新医疗器械领域不断取得突破。Insight Lifetech 的成功上市不仅是对国内心血管创新医疗器械发展路径的重要验证，也展示了中国在医疗技术创新方面的全球竞争力迅速提升。启明创投相信，中国的临床经验、工程能力和创业精神以及供应链优势能够培养出一代具有全球竞争力的创新医疗器械产品。我们希望与有抱负的企业家合作，开发高质量的产品，共同建设来自中国的伟大医疗器械公司，&#34; 启明创投合伙人 Oscar Zhang 表示。</p>
<p>关于启明创投</p>
<p>启明创投成立于 2006 年。目前，启明创投管理着 11 只美元基金和 7 只人民币基金，募集资金达到 95 亿美元。自成立以来，我们在科技和医疗健康行业的早期和成长阶段投资了众多优秀公司。</p>
<p>自成立以来，我们已支持超过 580 家快速增长和创新的公司。超过 210 家我们的投资组合公司通过在纽约证券交易所、纳斯达克、香港交易所、上海证券交易所或深圳证券交易所的 IPO，或通过并购等方式实现了退出。还有超过 80 家投资组合公司已达到独角兽或超级独角兽的地位。</p>
<p>我们的许多投资组合公司是各自领域中最具影响力的公司，包括小米、美团、哔哩哔哩、知乎、石头科技、禾赛科技、优必选、威来、HyperStrong、Insta360、云知声、比仁科技、Z.ai、甘李药业、泰格医药、再鼎医药、康希诺生物、施克德、APT 医疗、三友医疗、AmoyDx、华大基因、Insilico Medicine、AusperBio、元信科技、Medilink Therapeutics、LaNova Medicines、StepFun 等。</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA1Jk5ld3NJdGVtSWQ9RU44MDU2MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDUwNTM1UFJfTkVXU19FVVJPX05EX19FTjgwNTYx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA1Jk5ld3NJdGVtSWQ9RU44MDU2MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDUwNTM1UFJfTkVXU19FVVJPX05EX19FTjgwNTYx"/></p>

招商中证生物科技主题ETF

招商中证全指医疗器械ETF

北芯生命-U

华夏中证全指医疗器械ETF

华夏中证生物科技主题ETF

医疗器械ETF

易方达中证生物科技主题ETF

生物科技ETF基金

<p>华夏中证生物科技主题 ETF，一家领先的中国创新医疗器械制造商，已成功在上海证券交易所的科创板上市。该公司以每股 17.52 元人民币发行股票，开盘价为 50.31 元人民币，市值达到 209.8 亿元人民币。华夏中证生物科技主题 ETF 成立于 2015 年，专注于精准心血管解决方案，并开发了 IVUS 和 FFR 等关键产品。此次首次公开募股标志着中国医疗器械创新的一个重要里程碑，展示了该国在医疗科技领域日益增强的竞争力</p>

<p>, /PRNewswire/ -- Insight Lifetech, a portfolio company of Qiming Venture Partners and a leading Chinese innovative medical device manfaucturer, successfully listed on the Shanghai Stock Exchange's STAR Market on February 5, 2026 Beijing time. Insight Lifetech (688712.SH) issued shares at a price of CNY17.52 per share and opened at CNY50.31 per share with a market capitalization of CNY20.98 billion.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Insight Lifetech，启明创投的投资组合公司，作为中国领先的创新医疗器械制造商，于 2026 年 2 月 5 日北京时间成功在上海证券交易所科创板上市。Insight Lifetech (688712.SH) 以每股 17.52 元人民币的价格发行股票，开盘价为每股 50.31 元人民币，市值为 209.8 亿元人民币。</p>
</div><p>Qiming Venture Partners led the C round financing of Insight Lifetech in 2020 and continued to fund the company's development in the D round. Before the company's IPO, Qiming Venture Partners held a more than 6% stake in Insight Lifetech and was one of its major institutional investors.</p>
<div class="lb-trans"><p>启明创投在 2020 年主导了 Insight Lifetech 的 C 轮融资，并在 D 轮继续支持公司的发展。在公司上市前，启明创投持有 Insight Lifetech 超过 6% 的股份，是其主要机构投资者之一。</p>
</div><p>Founded in 2015, Insight Lifetech is dedicated tondeveloping innovative solutions with the potential to transform precision diagnosis and treatment of cardiovascular diseases. The company is the only domestic medical device company in China with a product portfolio in both precision intravascular physiology and imaging, including the first and only domestic fractional flow reserve (FFR) system approved by NMPA in China, and intravascular ultrasound (IVUS) system, which was the first domestic IVUS system to have entered clinical trialsand completed patient enrollment.</p>
<div class="lb-trans"><p>Insight Lifetech 成立于 2015 年，致力于开发具有潜力改变心血管疾病精准诊断和治疗的创新解决方案。该公司是中国唯一一家在精准血管生理学和成像领域拥有产品组合的国内医疗器械公司，包括中国首个也是唯一一个获得 NMPA 批准的分数流量储备（FFR）系统，以及进入临床试验并完成患者招募的首个国内血管内超声（IVUS）系统。</p>
</div><p>Since its establishment, Insight Lifetech has continuously invested in the fields of coronary artery diseases, peripheral vascular diseases, and atrial fibrillation based on the clinical needs of cardiovascular disease diagnosis and the development of cutting-edge technologies. It has now brought 11 products into the market and has more products under development in diverse categories, including IVUS system, FFR system, vascular access products, and electrophysiological solutions, etc.</p>
<div class="lb-trans"><p>自成立以来，Insight Lifetech 根据心血管疾病诊断的临床需求和前沿技术的发展，持续投资于冠状动脉疾病、外周血管疾病和房颤等领域。现在已将 11 款产品推向市场，并在多种类别中开发更多产品，包括 IVUS 系统、FFR 系统、血管通路产品和电生理解决方案等。</p>
</div><p>The company's core product, the IVUS system, is the first independently-developed 60MHz high-definition high-speed IVUS product approved in China and the first China-made product approved by CE MDR. The product gained the largest market share in China and reduced the country's dependence on imported products immediately after coming into the market. The FFR system, another core product of the company, is China's first approved domestically-made product in FFR field and the first China-made product approved to to overseas (by CE MDR). The two products are expected to help enhance the clinical practice of precision-guided percutaneous coronary intervention (PCI) surgeries.</p>
<div class="lb-trans"><p>公司的核心产品 IVUS 系统是中国首个自主研发的 60MHz 高清高速 IVUS 产品，也是首个获得 CE MDR 批准的中国制造产品。该产品在上市后迅速获得了中国市场的最大份额，减少了国家对进口产品的依赖。公司的另一核心产品 FFR 系统是中国首个获得批准的国产 FFR 产品，也是首个获得海外（由 CE MDR）批准的中国制造产品。这两款产品预计将有助于提升精准导向经皮冠状动脉介入（PCI）手术的临床实践。</p>
</div><p>Song Liang, Founder, Chairman &amp; CEO of Insight Lifetech stated，&#34;Since establishment, Insight Lifetech has consistently adhered to the mission 'To transform healthcare through innovation and quality', dedicating to innovating intelligence-powered precision cardiovascular intervention. With unwavering passion and relentless effort, we have filled a critical gap in China's medical device industry—a sector characterized by the highest technological barriers and the longest industrial chain: high-performance precision cardiovascular interventional devices.</p>
<div class="lb-trans"><p>Insight Lifetech 的创始人、董事长兼首席执行官宋亮表示：&#34;自成立以来，Insight Lifetech 始终坚持 ‘通过创新和质量改变医疗保健’ 的使命，致力于创新智能化精准心血管介入。凭借坚定的热情和不懈的努力，我们填补了中国医疗器械行业的一个关键空白——这是一个技术壁垒最高、产业链最长的领域：高性能精准心血管介入设备。</p>
</div><p>Moving forward, we will continue to hold our position at the forefront of innovation in precision cardiovascular intervention, remain clinically focused, pursue uncompromising quality, and demonstrate the robust power of Chinese innovation to the world. &#34;</p>
<div class="lb-trans"><p>展望未来，我们将继续保持在精准心血管介入创新的前沿，保持临床聚焦，追求无可妥协的质量，向世界展示中国创新的强大力量。&#34;</p>
</div><p>&#34;Insight Lifetech is deeply committed to transfer clinical insights and technological capabilities to innovative and differentiated ntherapies in the cardiovascular intervention field, for the benefits of patients and physicians, worldwide. The dedicated team convinced us that it can make continuous breakthroughs in the field of innovative medical devices. The successful IPO of Insight Lifetech is not only an important verification of the development path of domestic cardiovascular innovative medical devices, but also demonstrates the rapid rise of China's global competitiveness in medtech innovation. Qiming Venture Partners believes that China's clinical experience, engineering capabilities, and entrepreneurship as well as advantages in supply chains can cultivate a generation of innovative medical device products which are competitive worldwide. We hope to work with ambitious entrepreneurs, to develophigh-quality products, and to co-build great medical device companies from China,&#34; Oscar Zhang, a partner of Qiming Venture Partners, said.</p>
<div class="lb-trans"><p>&#34;Insight Lifetech 深切致力于将临床洞察和技术能力转化为心血管介入领域的创新和差异化疗法，造福全球患者和医生。这个专注的团队让我们相信它能够在创新医疗器械领域不断取得突破。Insight Lifetech 的成功上市不仅是对国内心血管创新医疗器械发展路径的重要验证，也展示了中国在医疗技术创新方面的全球竞争力迅速提升。启明创投相信，中国的临床经验、工程能力和创业精神以及供应链优势能够培养出一代具有全球竞争力的创新医疗器械产品。我们希望与有抱负的企业家合作，开发高质量的产品，共同建设来自中国的伟大医疗器械公司，&#34; 启明创投合伙人 Oscar Zhang 表示。</p>
</div><p>About Qiming Venture Partners</p>
<div class="lb-trans"><p>关于启明创投</p>
</div><p>Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.</p>
<div class="lb-trans"><p>启明创投成立于 2006 年。目前，启明创投管理着 11 只美元基金和 7 只人民币基金，募集资金达到 95 亿美元。自成立以来，我们在科技和医疗健康行业的早期和成长阶段投资了众多优秀公司。</p>
</div><p>Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&amp;A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.</p>
<div class="lb-trans"><p>自成立以来，我们已支持超过 580 家快速增长和创新的公司。超过 210 家我们的投资组合公司通过在纽约证券交易所、纳斯达克、香港交易所、上海证券交易所或深圳证券交易所的 IPO，或通过并购等方式实现了退出。还有超过 80 家投资组合公司已达到独角兽或超级独角兽的地位。</p>
</div><p>Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan &amp; Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.</p>
<div class="lb-trans"><p>我们的许多投资组合公司是各自领域中最具影响力的公司，包括小米、美团、哔哩哔哩、知乎、石头科技、禾赛科技、优必选、威来、HyperStrong、Insta360、云知声、比仁科技、Z.ai、甘李药业、泰格医药、再鼎医药、康希诺生物、施克德、APT 医疗、三友医疗、AmoyDx、华大基因、Insilico Medicine、AusperBio、元信科技、Medilink Therapeutics、LaNova Medicines、StepFun 等。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA1Jk5ld3NJdGVtSWQ9RU44MDU2MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDUwNTM1UFJfTkVXU19FVVJPX05EX19FTjgwNTYx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN80561&amp;Transmission_Id=202602050535PR_NEWS_EURO_ND__EN80561&amp;DateId=20260205"/></p>

领先的中国创新医疗器械制造商 C 北芯-U 成功在科创板上市